98%
921
2 minutes
20
It has been widely demonstrated that time processing is altered in patients with schizophrenia. This perspective review delves into such temporal deficit and highlights its link to low-level sensory alterations, which are often overlooked in rehabilitation protocols for psychosis. However, if temporal impairment at the sensory level is inherent to the disease, new interventions should focus on this dimension. Beyond more traditional types of intervention, here we review the most recent digital technologies for rehabilitation and the most promising ones for sensory training. The overall aim is to synthesise existing literature on time in schizophrenia linking psychopathology, psychophysics, and technology to help future developments.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9374791 | PMC |
http://dx.doi.org/10.1038/s41398-022-02101-x | DOI Listing |
Adv Ther
September 2025
Teva Branded Pharmaceutical Products R&D LLC, West Chester, PA, USA.
Introduction: Pharmacokinetic differences between long-acting injectable antipsychotic (LAI) formulations, combined with a lack of clinical switch studies, contribute to clinician uncertainty when transitioning between LAIs. This analysis employed a population pharmacokinetic (popPK) modeling approach to characterize dosing conversions and switching strategies from intramuscular paliperidone palmitate once monthly (PP1m) to TV-46000, a long-acting subcutaneous formulation of risperidone, once monthly (q1m), with a secondary analysis of PP1m to TV-46000 every 2 months (q2m).
Methods: For PP1m and TV-46000, concentration-time profiles for paliperidone and TV-46000 total active moiety (TAM; risperidone + paliperidone) were simulated on the basis of published popPK models with virtual populations of 5000 patients.
Indian J Psychiatry
August 2025
Department of Psychiatry, Serenity Clinic, New Delhi, India.
Background: Cognitive deficits significantly contribute to the disability related to schizophrenia.
Aim: We aim to evaluate the efficacy of high-frequency rTMS intervention in the improvement of cognitive symptoms in schizophrenia.
Methods: One-hundred patients of predominantly negative schizophrenia having cognitive deficits were enrolled for this randomized, sham controlled, double-blind trial.
Front Psychiatry
August 2025
Statistics Section of the Department of Genetics, Microbiology and Statistics, Universitat de Barcelona (UB), Barcelona, Spain.
Most methodological Polygenic Risk Score (PRS)-related papers explain the laborious process of computing the PRS in great depth. Afterwards, as a last step, it is generally described that to test a possible association between a PRS and a trait of interest, an analysis through regression models (linear or logistic, depending on data type) should be carried out adjusting for covariates (e.g.
View Article and Find Full Text PDFFront Biosci (Landmark Ed)
August 2025
Laboratory of Molecular Biology, Research Centre for Medical Genetics (RCMG), 115522 Moscow, Russia.
Background: Schizophrenia (SZ) is associated with chronic oxidative stress in the patient's body. Previous studies revealed an increased copy number of genes for 47S pre-ribosomal RNA (pre-rRNA) in SZ patients. In this study, levels of oxidative stress and factors involved in the adaptive response to chronic stress (rDNA transcription) were, for the first time, compared in blood cells of patients with catatonic SZ(C) and paranoid SZ(P), chronic forms of schizophrenia, as well as healthy controls (HC).
View Article and Find Full Text PDFAsian J Psychiatr
September 2025
Department of Psychiatry and Mental Health, Faculty of Medicine, Universidad de Chile, Santiago, Chile; Translational Psychiatry Laboratory (Psiquislab), Faculty of Medicine, Universidad de Chile, Santiago, Chile; Millennium Nucleus to Improve the Mental Health of Adolescents and Youths (IMHAY), San
Background: Schizophrenia spectrum disorders often emerge in adolescence or early adulthood and are a leading cause of global disability. Early identification of clinical high‑risk for psychosis (CHR‑P) can reduce comorbidity and shorten untreated psychosis duration, yet clinician‑administered tools (e.g.
View Article and Find Full Text PDF